Many people take GLP-1 medications for months or years. This guide explains what changes over that longer timeframe, including NHS time limits, private access, monitoring, safety data and cost.
"Long-term" is a relative term here
These medications have been licensed in the UK for weight management between 2021 (semaglutide, sold as Wegovy) and 2023 (tirzepatide, sold as Mounjaro), though widespread NHS and private use only began around 2023. Ozempic contains the same active ingredient as Wegovy but is licensed for type 2 diabetes, not weight loss. Any use of Ozempic for weight loss is off-label.
This means:
- Long-term usually means dedicated weight-loss trial data extending to about 2 years for semaglutide, and around 88 weeks (about 1.7 years) for tirzepatide
- Longer safety data, up to around 5 years, exist from separate cardiovascular outcome trials, but these are not weight-loss efficacy trials
- Nobody has 10 or 20-year safety data yet, because the medications have not been around that long
- Real-world data (from millions of people using the drugs, not just trial participants) is still building up
"Long-term" claims currently mean "the longest period measured so far", not "what happens after decades".
There is no long-term data yet on outcomes after 5 plus years of continuous use, or on staying at a low maintenance dose indefinitely rather than stopping. This is still being studied.
How long can you stay on GLP-1 medication on the NHS?
If you're getting a GLP-1 medication through the NHS, the rules differ depending on the drug.
- For semaglutide (Wegovy), NICE guidance caps NHS prescribing at a maximum of 2 years, delivered within a specialist weight management service
- For tirzepatide (Mounjaro), NICE guidance sets no fixed time limit, and it can be prescribed in primary care as well as specialist services
- NICE guidance recommends stopping if you haven't lost a meaningful amount of weight within the first 6 months, judged by your prescriber. Ask your prescriber how this applies to your treatment
- After any time limit or stopping point, continued access depends on local commissioning decisions and your specific pathway, not just clinical need
- Some ICBs (Integrated Care Boards) have tighter local criteria or longer waiting lists than others, so what's available can depend on where you live
Some people reach the NHS time limit or stopping point while still wanting to continue treatment. At that point, the choice is between NHS reassessment if eligible, stopping, or moving to private prescribing.
Source: NHS England commissioning guidance.
Unsure if you're eligible for
weight loss medication - on the NHS or privately?
Check your eligibility in under 2 minutes with our free GLP-1 eligibility checker.
Check your eligibility- A personalised result in under 2 minutes
- Covers both NHS and private routes
- No sign-up needed
Private access: no fixed time limit
Private prescribing is more flexible - you can continue for as long as you're assessed as clinically suitable. See our NHS vs private GLP-1 comparison for a fuller breakdown of both routes.
- Private clinics and pharmacies typically require repeat consultations, often every 3 to 6 months, to keep prescribing. This interval is set by the individual provider in line with regulatory requirements for ongoing clinical follow-up, there's no single fixed legal requirement for the exact frequency
- There's no clinical consensus on an "ideal" length of treatment, so decisions about stopping or continuing are made case by case with your prescriber
- Cost becomes the main practical constraint, covered below
Compare private prices for weight loss medications
See costs by dose, and exactly what's included in each price upfront - so you can choose the best option for you.
What you'll get
- Prices from regulated pharmacies only
- See costs side by side, no sign-up
- Know what safety checks to expect
Monitoring over time
Whether you're on the NHS or going private, ongoing use means ongoing checks, not a one-off assessment.
Typical monitoring over the course of long-term treatment includes:
- Regular weight and BMI tracking
- Blood tests, for things like kidney function and blood glucose, if your prescriber judges these are needed, there's no single fixed testing schedule for weight-management use
- Checks for side effects, including gastrointestinal symptoms, gallbladder issues and pancreatitis risk
- A review of whether the medication is still the right fit, especially if your dose has been stable for a long time
Source: NICE and MHRA prescribing guidance.
Private prescriptions are usually tied to an active review. If a review lapses, your prescription may lapse too.
Is it safe to take GLP-1 medication long-term?
What long-term data currently shows:
Trial data up to around 2 years covers both outcomes and risks. Reported outcomes include weight loss and changes in markers like blood pressure and cholesterol. Reported risks include:
- Known and monitored side effects, including gastrointestinal symptoms (common), gallbladder problems, and rarer but serious risks like pancreatitis
- Ongoing research into thyroid-related risks, based on animal studies, though this has not been confirmed as a significant risk in humans at this stage. UK product information does not list this as a contraindication, though some prescribers ask about personal or family history of thyroid cancer as a precaution
- Weight regain after stopping, which is common and well documented
Ongoing monitoring, like with any long-term medication, is how changes or side effects are picked up over time.
Source: MHRA and NICE guidance on GLP-1 medications.
Costs of staying on treatment
This is where NHS and private routes diverge most sharply. NHS treatment is free at the point of use within your eligibility window. Private treatment is an ongoing cost for as long as you continue.
| NHS | Private | |
|---|---|---|
| Cost at point of use | Free in Scotland, Wales and Northern Ireland. In England, the standard prescription charge is £9.90 per item | Full cost, roughly £100 to £375 per month, depending on drug and dose, as of mid-2026 |
| Time limit | Wegovy: capped at 2 years. Mounjaro: no fixed time limit | No fixed limit, ongoing while clinically appropriate |
| Consultations included | Included as part of NHS pathway | Usually charged separately, every 3 to 6 months |
| Estimated cost over 3 years (private) | N/A | Roughly £3,600 to £13,500, before consultation fees |
| Access consistency | Varies by ICB and local pathway | Consistent, subject to ongoing clinical assessment |
Private prices vary between providers and have changed significantly within the past year, so treat these figures as a general guide rather than a current quote. Use the price comparison tool below for up to date figures.
Costs above include medication only unless stated. Consultation fees are usually separate.
Compare current private GLP-1 prices: use our live price comparison tool to see what different providers are charging right now.
Frequently asked questions
Sources
- NICE TA875: Semaglutide for managing overweight and obesity
- NICE TA1026: Tirzepatide for managing overweight and obesity
- MHRA: Medicines and Healthcare products Regulatory Agency
- Wegovy Summary of Product Characteristics (electronic Medicines Compendium)
- Mounjaro Summary of Product Characteristics (electronic Medicines Compendium)
- NHS England: commissioning guidance
- NHS: help with prescription costs
- General Pharmaceutical Council (GPhC): guidance for pharmacies offering weight management services